INNOVADERM CRO IS NOW INDERO.
READ THE ANNOUNCEMENT
Talk to us

The Potential of Adaptive Design in Clinical Trials

Diane Potvin

Diane Potvin

Senior Statistical Advisor

Author picture

Did you know? Adaptive design offers numerous benefits that streamline the drug-development process and bring life-changing medications to patients more rapidly.

Adaptive Study Design Help With:

  • Reducing the costs of drug development
  • Contributing to reducing the length of the trial
  • Reducing the time to bring a drug to the market
  • Allowing patients to access to the medication more rapidly

Click this link to download the PDF version.

Read the full article: Potvin D, D’Angelo P, Bennett S, Jankicevic J, Bissonnette R. Adaptive designs in dermatology clinical trials: Current status and future perspectives. J Eur Acad Dermatol Venereol. 2024 Apr 15. doi: 10.1111/jdv.20030. Epub ahead of print. PMID: 38619384. 

SHARE THIS POST

Subscribe to our newsletter.

Do not miss out on valuable insights and research updates. Join our scientific community today!

This field is for validation purposes and should be left unchanged.
Talk to us

Jeff Smith

Chef de la direction
Linkedin

Jeff Smith, Chef de la direction d’Indero Recherches, apporte près de 30 ans d’expérience dans l’industrie pharmaceutique et CRO, s’étant distingué par son leadership exceptionnel, sa vision stratégique et son innovation. L’expertise de Jeff couvre des opérations mondiales, la gestion de la croissance, ainsi que la promotion d’une culture d’entreprise collaborative. Ses atouts en matière de création de valeur, de gestion des partenaires et d’opérations CRO ont toujours contribué au succès dans ses fonctions précédentes. Sous la direction de Jeff, Indero continue d’étendre ses capacités, faisant progresser les connaissances médicales et les nouvelles thérapies en dermatologie et en rhumatologie.

Revolutionize Your Topical Trials

Efficacy insights in days, not months.

 Indero’s Early Phase 1 model enables sponsors to initiate topical studies that detect early pharmacodynamic signals much sooner than traditional phase 1, using microdosing and transcriptomic analysis. This approach reduces preclinical requirements, shortens study duration from 8–12 weeks to ≤3 days, and lowers costs, helping teams make informed go/no-go decisions faster.
LEARN MORE >